gefitinib has been researched along with cinobufagin in 1 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (cinobufagin) | Trials (cinobufagin) | Recent Studies (post-2010) (cinobufagin) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 133 | 2 | 78 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dai, L; Hu, ZD; Li, XL; Sun, YX; Tao, YF; Wang, AM; Wang, SP; Wu, Q; Yang, AL; Zhang, J | 1 |
1 other study(ies) available for gefitinib and cinobufagin
| Article | Year |
|---|---|
A network pharmacology approach to investigate the anticancer mechanism of cinobufagin against hepatocellular carcinoma via downregulation of EGFR-CDK2 signaling.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bufanolides; Carcinoma, Hepatocellular; Cell Proliferation; Cyclin-Dependent Kinase 2; Down-Regulation; Drug Synergism; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Hep G2 Cells; Humans; Liver Neoplasms; M Phase Cell Cycle Checkpoints; Network Pharmacology; Protein Interaction Maps; Protein Kinase Inhibitors; Purines; Signal Transduction | 2021 |